In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment.

Autor: van Boven N; Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands.; Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands., Akkerhuis KM; Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands., Anroedh SS; Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands., Battes LC; Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands., Caliskan K; Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands., Yassi W; Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands., Manintveld OC; Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands., Cornel JH; Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands., Constantinescu AA; Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands., Boersma H; Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands., Umans VA; Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands., Kardys I; Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands. i.kardys@erasmusmc.nl.
Jazyk: angličtina
Zdroj: Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation [Neth Heart J] 2017 Nov; Vol. 25 (11), pp. 634-642.
DOI: 10.1007/s12471-017-1040-x
Abstrakt: Introduction: Blood biomarkers have the potential to monitor the severity of chronic heart failure (CHF). Studies correlating repeated measurements of blood biomarkers with repeatedly assessed New York Heart Association (NYHA) class over a prolonged follow-up period, and concomitantly investigating their associations with clinical endpoints, have not yet been performed.
Methods: Between 2011-2013, 263 CHF patients were included. At inclusion and subsequently every 3 months, we measured N‑terminal pro-B-type natriuretic (NT-proBNP), high-sensitivity troponin T (Hs-TnT) and C‑reactive protein (CRP), and assessed NYHA class. The primary endpoint comprised heart failure hospitalisation, cardiovascular mortality, cardiac transplantation or left ventricular assist device implantation. Time-dependent Cox models were used.
Results: Mean age was 67 ± 13 years, 72% were men and 27% were in NYHA class III-IV. We obtained 886 repeated measures (median 3 [IQR 2-5] per patient). The primary endpoint was reached in 41 patients during a median follow-up of 1.0 [0.6-1.4] year. Repeatedly measured NT-proBNP and Hs-TnT were significantly associated with repeatedly assessed NYHA class, whereas CRP was not (NT-proBNP: β [95% CI]: 1.56 [1.17-2.06]ln(ng/l) increase per point increase in NYHA class, p = 0.002; HsTNT: β [95% CI]: 1.58 [1.21-2.07]). Serially measured NT-proBNP (HR [95% CI]:2.86 [1.73-4.73]), CRP (1.69 [1.21-2.34]) and NYHA class (2.33 [1.51-3.62]) were positively and independently associated with the primary endpoint, whereas Hs-TnT lost statistical significance after multivariable adjustment. A model containing serially measured NYHA class and NT-proBNP displayed a C-index of 0.84, while serially measured NYHA class and CRP showed a C-index of 0.82.
Conclusion: Temporal NT-proBNP, CRP and NYHA class patterns are independently associated with adverse clinical outcome. Serially measured NT-proBNP and NYHA class are best suited for monitoring CHF outpatients.
Databáze: MEDLINE
Externí odkaz: